Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814151 | 0.84 | CYP11B2 (0.51) | CYP11B2CYP11B1 | |
| SCHEMBL17814133 | 0.84 | CYP11B2 (0.47) | CYP11B2CYP11B1 | |
| SCHEMBL17814129 | 0.81 | CYP11B2 (0.46) | CYP11B2CYP11B1 | |
| SCHEMBL19348326 | 0.80 | MAPK14 (0.41) | CYP11B2CYP11B1MAPK14BRD4 | |
| SCHEMBL17814147 | 0.80 | CYP11B2 (0.49) | CYP11B2CYP11B1 | |
| SCHEMBL17814161 | 0.79 | MAPK14 (0.42) | CYP11B2CYP11B1MAPK14BRD4 | |
| SCHEMBL17814139 | 0.77 | CYP11B1 (0.57) | CYP11B2CYP11B1 | |
| SCHEMBL17814108 | 0.77 | CYP11B1 (0.49) | CYP11B2CYP11B1BRD4 | |
| SCHEMBL17814095 | 0.76 | CYP11B1 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL17814146 | 0.76 | CYP11B1 (0.49) | CYP11B2CYP11B1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | CYP11B2 3/4885CYP11B1 1/4885MAPK14 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.